We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.73B
AUM Growth
+$239M
Cap. Flow
+$39.4M
Cap. Flow %
2.27%
Top 10 Hldgs %
27.21%
Holding
142
New
9
Increased
33
Reduced
17
Closed
2

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$27.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$20.9M
3
PCRX icon
Pacira BioSciences
PCRX
+$12.4M
4
AFAM
Almost Family Inc
AFAM
+$10.8M
5
OBSV
ObsEva SA Ordinary Shares
OBSV
+$10.3M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.7M
2
TSRO
TESARO, Inc.
TSRO
+$22.6M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.3M
4
MEDP icon
Medpace
MEDP
+$4.87M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.11M

Sector Composition

Rank Sector Weight
1 Healthcare 82.21%
2 Financials 2.45%
3 Consumer Discretionary 0.63%
4 Industrials 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KA
101
DELISTED
Kineta, Inc. Common Stock
KA
$3.52M 0.2%
3,214
– –
PBYI icon
102
Puma Biotechnology
PBYI
$454M
$3.52M 0.2%
94,500
– –
MDGL icon
103
Madrigal Pharmaceuticals
MDGL
$11.8B
$3.46M 0.2%
225,000
+50,109
+29% +$788K
RIGL icon
104
Rigel Pharmaceuticals
RIGL
$750M
$3.31M 0.19%
100,000
– –
INVA icon
105
Innoviva
INVA
$1.48B
$3.25M 0.19%
235,000
-101,900
-30% -$1.2M
GKOS icon
106
Glaukos
GKOS
$10.6B
$3.21M 0.19%
+62,500
New +$2.72M
HRC
107
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$3.18M 0.18%
45,000
-2,500
-5% -$159K
ITCI
108
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.09M 0.18%
190,000
– –
GNCA
109
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.92M 0.17%
60,000
– –
BLUE
110
DELISTED
bluebird bio
BLUE
$2.77M 0.16%
2,355
+155
+7% +$158K
TVRD
111
Tvardi Therapeutics
TVRD
$23.4M
$2.76M 0.16%
+4,167
New +$2.23M
ZBH icon
112
Zimmer Biomet
ZBH
$18.4B
$2.58M 0.15%
21,733
– –
OTIC
113
DELISTED
Otonomy, Inc.
OTIC
$2.57M 0.15%
210,000
– –
DBVT
114
DBV Technologies
DBVT
$847M
$2.57M 0.15%
7,300
– –
MCRB icon
115
Seres Therapeutics
MCRB
$48.4M
$2.48M 0.14%
11,000
– –
CDTX
116
DELISTED
Cidara Therapeutics
CDTX
$2.34M 0.14%
15,000
– –
NDRM
117
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.23M 0.13%
+84,079
New +$2.08M
HQY icon
118
HealthEquity
HQY
$8.75B
$2.12M 0.12%
50,000
– –
SCYX icon
119
SCYNEXIS
SCYX
$52M
$2.1M 0.12%
9,500
– –
MYOV
120
DELISTED
Myovant Sciences Ltd.
MYOV
$1.76M 0.1%
150,000
+60,400
+67% +$692K
ALPN
121
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.75M 0.1%
150,000
+27,750
+23% +$281K
NVCR icon
122
NovoCure
NVCR
$1.91B
$1.74M 0.1%
214,316
– –
ATYR
123
aTyr Pharma
ATYR
$50.1M
$1.66M 0.1%
33,929
– –
LUMO
124
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.62M 0.09%
+7,452
New +$1.06M
EGLT
125
DELISTED
Egalet Corporation
EGLT
$1.53M 0.09%
300,000
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Rock Springs Capital Management held 142 positions worth $1.73B, up 16% from $1.49B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q1 2017 filing shows 9 new, 33 increased, 17 reduced and 2 closed positions. Its largest new stake was Humana: 132,500 shares worth $27.3M. The largest sale was Aetna Inc, an estimated $27.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q1 2017 buy was Humana: 132,500 shares worth $27.3M.
  • Rock Springs Capital Management added most to Pacira BioSciences in Q1 2017, an estimated $12.4M increase.
  • Rock Springs Capital Management's biggest Q1 2017 reduction was Aetna Inc, cutting an estimated $27.7M.
  • Rock Springs Capital Management fully exited Medpace in Q1 2017, selling an estimated $4.87M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.73B portfolio in Q1 2017.
  • Rock Springs Capital Management opened 9 new positions and closed 2 in Q1 2017.
  • Rock Springs Capital Management's portfolio value rose 16% quarter-over-quarter to $1.73B.

Based on Rock Springs Capital Management's 13F filing for Q1 2017, filed 15 May 2017.